MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-

[News]

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

More... (http://www.news-medical.net/news/20140916/MOVANTIK-tablets-get-FDA-approval-for-treatment-of-OIC-in-patients-with-chronic-non-cancer-pain.aspx)